Fidelity Investments
LBRX

Fidelity Investments’s LB Pharmaceuticals LBRX Stock Holding History

Fidelity Investments’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.49M Buy
222,508
+643
+0.3% +$14.8K ﹤0.01% 2274
2025
Q4 		$4.94M Sell
221,865
-147,235
-40% -$2.57M ﹤0.01% 2292
2025
Q3 		$5.83M Buy
+369,100
New +$5.86M ﹤0.01% 2191

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Fidelity Investments's LBRX Position: Q1 2026 in Review

Fidelity Investments increased its LB Pharmaceuticals (LBRX) stake by 0.29% in Q1 2026, buying an estimated $14.8K and bringing the position to 222,508 shares worth $5.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2274.

Fidelity Investments first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.83M in Q3 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Fidelity Investments held 222,508 shares of LB Pharmaceuticals worth $5.49M as of Q1 2026.
  • Fidelity Investments bought 643 LB Pharmaceuticals shares in Q1 2026, an estimated $14.8K.
  • LB Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2274 holding.
  • Fidelity Investments first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Fidelity Investments's LB Pharmaceuticals position peaked at $5.83M in Q3 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.